8
|
Hobeika C, Fuks D, Cauchy F, Goumard C, Soubrane O, Gayet B, Salamé E, Cherqui D, Vibert E, Scatton O, Nomi T, Oudafal N, Kawai T, Komatsu S, Okumura S, Petrucciani N, Laurent A, Bucur P, Barbier L, Trechot B, Nunèz J, Tedeschi M, Allard MA, Golse N, Ciacio O, Pittau G, Cunha AS, Adam R, Laurent C, Chiche L, Leourier P, Rebibo L, Regimbeau JM, Ferre L, Souche FR, Chauvat J, Fabre JM, Jehaes F, Mohkam K, Lesurtel M, Ducerf C, Mabrut JY, Hor T, Paye F, Balladur P, Suc B, Muscari F, Millet G, El Amrani M, Ratajczak C, Lecolle K, Boleslawski E, Truant S, Pruvot FR, Kianmanesh AR, Codjia T, Schwarz L, Girard E, Abba J, Letoublon C, Chirica M, Carmelo A, VanBrugghe C, Cherkaoui Z, Unterteiner X, Memeo R, Pessaux P, Buc E, Lermite E, Barbieux J, Bougard M, Marchese U, Ewald J, Turini O, Thobie A, Menahem B, Mulliri A, Lubrano J, Zemour J, Fagot H, Passot G, Gregoire E, Hardwigsen J, le Treut YP, Patrice D. Impact of cirrhosis in patients undergoing laparoscopic liver resection in a nationwide multicentre survey. Br J Surg 2020; 107:268-277. [PMID: 31916594 DOI: 10.1002/bjs.11406] [Citation(s) in RCA: 40] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2019] [Revised: 09/21/2019] [Accepted: 09/27/2019] [Indexed: 12/21/2022]
Abstract
BACKGROUND The aim was to analyse the impact of cirrhosis on short-term outcomes after laparoscopic liver resection (LLR) in a multicentre national cohort study. METHODS This retrospective study included all patients undergoing LLR in 27 centres between 2000 and 2017. Cirrhosis was defined as F4 fibrosis on pathological examination. Short-term outcomes of patients with and without liver cirrhosis were compared after propensity score matching by centre volume, demographic and tumour characteristics, and extent of resection. RESULTS Among 3150 patients included, LLR was performed in 774 patients with (24·6 per cent) and 2376 (75·4 per cent) without cirrhosis. Severe complication and mortality rates in patients with cirrhosis were 10·6 and 2·6 per cent respectively. Posthepatectomy liver failure (PHLF) developed in 3·6 per cent of patients with cirrhosis and was the major cause of death (11 of 20 patients). After matching, patients with cirrhosis tended to have higher rates of severe complications (odds ratio (OR) 1·74, 95 per cent c.i. 0·92 to 3·41; P = 0·096) and PHLF (OR 7·13, 0·91 to 323·10; P = 0·068) than those without cirrhosis. They also had a higher risk of death (OR 5·13, 1·08 to 48·61; P = 0·039). Rates of cardiorespiratory complications (P = 0·338), bile leakage (P = 0·286) and reoperation (P = 0·352) were similar in the two groups. Patients with cirrhosis had a longer hospital stay than those without (11 versus 8 days; P = 0·018). Centre expertise was an independent protective factor against PHLF in patients with cirrhosis (OR 0·33, 0·14 to 0·76; P = 0·010). CONCLUSION Underlying cirrhosis remains an independent risk factor for impaired outcomes in patients undergoing LLR, even in expert centres.
Collapse
Affiliation(s)
- C Hobeika
- Department of Hepatobiliary and Pancreatic Surgery and Liver Transplantation, Sorbonne Université, Centre de Recherche Scientifique Saint Antoine, Hôpital Pitié Salpétrière, Paris, France
| | - D Fuks
- Department of Digestive, Oncological and Metabolic Surgery, Institut Mutualiste Montsouris, University Paris Descartes, Paris, France
| | - F Cauchy
- Department of Hepatobiliary and Pancreatic Surgery and Liver Transplantation, Hôpital Beaujon, Clichy, France
| | - C Goumard
- Department of Hepatobiliary and Pancreatic Surgery and Liver Transplantation, Sorbonne Université, Centre de Recherche Scientifique Saint Antoine, Hôpital Pitié Salpétrière, Paris, France
| | - O Soubrane
- Department of Hepatobiliary and Pancreatic Surgery and Liver Transplantation, Hôpital Beaujon, Clichy, France
| | - B Gayet
- Department of Digestive, Oncological and Metabolic Surgery, Institut Mutualiste Montsouris, University Paris Descartes, Paris, France
| | - E Salamé
- Department of Digestive Surgery and Liver Transplantation, Trousseau University Hospital, Tours University, Tours, France
| | - D Cherqui
- Department of Hepatobiliary and Pancreatic Surgery and Liver Transplantation, Centre Hépato-biliaire de Paul Brousse, Villejuif, France
| | - E Vibert
- Department of Hepatobiliary and Pancreatic Surgery and Liver Transplantation, Centre Hépato-biliaire de Paul Brousse, Villejuif, France
| | - O Scatton
- Department of Hepatobiliary and Pancreatic Surgery and Liver Transplantation, Sorbonne Université, Centre de Recherche Scientifique Saint Antoine, Hôpital Pitié Salpétrière, Paris, France
| | | | - T Nomi
- Nara Medical University, Nara, Japan
| | - N Oudafal
- Institut Mutualiste Montsouris, Paris, France
| | - T Kawai
- Pitié Salpétrière Hospital, Assistance Publique - Hôpitaux de Paris (APHP), Paris, France
| | - S Komatsu
- Pitié Salpétrière Hospital, Assistance Publique - Hôpitaux de Paris (APHP), Paris, France
| | - S Okumura
- Pitié Salpétrière Hospital, Assistance Publique - Hôpitaux de Paris (APHP), Paris, France
| | | | - A Laurent
- Hôpital Henri Mondor, APHP, Creteil, France
| | - P Bucur
- Trousseau Hospital, University Hospital Centre of Tours, Tours, France
| | - L Barbier
- Trousseau Hospital, University Hospital Centre of Tours, Tours, France
| | - B Trechot
- Centre Hépato-biliaire de Paul Brousse, APHP, Villejuif, France
| | - J Nunèz
- Centre Hépato-biliaire de Paul Brousse, APHP, Villejuif, France
| | - M Tedeschi
- Centre Hépato-biliaire de Paul Brousse, APHP, Villejuif, France
| | - M-A Allard
- Centre Hépato-biliaire de Paul Brousse, APHP, Villejuif, France
| | - N Golse
- Centre Hépato-biliaire de Paul Brousse, APHP, Villejuif, France
| | - O Ciacio
- Centre Hépato-biliaire de Paul Brousse, APHP, Villejuif, France
| | - G Pittau
- Centre Hépato-biliaire de Paul Brousse, APHP, Villejuif, France
| | - A Sa Cunha
- Centre Hépato-biliaire de Paul Brousse, APHP, Villejuif, France
| | - R Adam
- Centre Hépato-biliaire de Paul Brousse, APHP, Villejuif, France
| | - C Laurent
- Hospital University Centre of Bordeaux, Bordeaux, France
| | - L Chiche
- Hospital University Centre of Bordeaux, Bordeaux, France
| | - P Leourier
- Hospital University Centre of Amiens-Picardie, Amiens, France
| | - L Rebibo
- Hospital University Centre of Amiens-Picardie, Amiens, France
| | - J-M Regimbeau
- Hospital University Centre of Amiens-Picardie, Amiens, France
| | - L Ferre
- Saint Eloi Hospital, Hospital University Centre of Montpellier, Montpellier, France
| | - F R Souche
- Saint Eloi Hospital, Hospital University Centre of Montpellier, Montpellier, France
| | - J Chauvat
- Saint Eloi Hospital, Hospital University Centre of Montpellier, Montpellier, France
| | - J-M Fabre
- Saint Eloi Hospital, Hospital University Centre of Montpellier, Montpellier, France
| | - F Jehaes
- Croix Rousse Hospital, Hospices Civils de Lyon, Lyon, France
| | - K Mohkam
- Croix Rousse Hospital, Hospices Civils de Lyon, Lyon, France
| | - M Lesurtel
- Croix Rousse Hospital, Hospices Civils de Lyon, Lyon, France
| | - C Ducerf
- Croix Rousse Hospital, Hospices Civils de Lyon, Lyon, France
| | - J-Y Mabrut
- Croix Rousse Hospital, Hospices Civils de Lyon, Lyon, France
| | - T Hor
- St Antoine Hospital, APHP, Paris, France
| | - F Paye
- St Antoine Hospital, APHP, Paris, France
| | - P Balladur
- St Antoine Hospital, APHP, Paris, France
| | - B Suc
- Rangueil Hospital, Hospital University Centre of Toulouse, Toulouse, France
| | - F Muscari
- Rangueil Hospital, Hospital University Centre of Toulouse, Toulouse, France
| | - G Millet
- Claude Huriez Hospital, Hospital University Centre of Lille, Lille, France
| | - M El Amrani
- Claude Huriez Hospital, Hospital University Centre of Lille, Lille, France
| | - C Ratajczak
- Claude Huriez Hospital, Hospital University Centre of Lille, Lille, France
| | - K Lecolle
- Claude Huriez Hospital, Hospital University Centre of Lille, Lille, France
| | - E Boleslawski
- Claude Huriez Hospital, Hospital University Centre of Lille, Lille, France
| | - S Truant
- Claude Huriez Hospital, Hospital University Centre of Lille, Lille, France
| | - F-R Pruvot
- Claude Huriez Hospital, Hospital University Centre of Lille, Lille, France
| | - A-R Kianmanesh
- Robert Debré Hospital, Hospital University Centre of Reims, Reims, France
| | - T Codjia
- Charles Nicolle Hospital, Hospital University Centre of Rouen, Rouen, France
| | - L Schwarz
- Charles Nicolle Hospital, Hospital University Centre of Rouen, Rouen, France
| | - E Girard
- Michalon Hospital, Hospital University Centre of Grenoble, Grebnoble, France
| | - J Abba
- Michalon Hospital, Hospital University Centre of Grenoble, Grebnoble, France
| | - C Letoublon
- Michalon Hospital, Hospital University Centre of Grenoble, Grebnoble, France
| | - M Chirica
- Michalon Hospital, Hospital University Centre of Grenoble, Grebnoble, France
| | | | | | - Z Cherkaoui
- Nouvel Hôpital Civil, Hospital University Centre of Strasbourg, Strasbourg, France
| | - X Unterteiner
- Nouvel Hôpital Civil, Hospital University Centre of Strasbourg, Strasbourg, France
| | - R Memeo
- Nouvel Hôpital Civil, Hospital University Centre of Strasbourg, Strasbourg, France
| | - P Pessaux
- Nouvel Hôpital Civil, Hospital University Centre of Strasbourg, Strasbourg, France
| | - E Buc
- Hospital University Centre of Clermont-Ferrand, Clermont-Ferrand, France
| | - E Lermite
- Hospital University Centre of Angers, Angers, France
| | - J Barbieux
- Hospital University Centre of Angers, Angers, France
| | - M Bougard
- Hospital University Centre of Angers, Angers, France
| | - U Marchese
- Institut Paoli-Calmettes, Marseille, France
| | - J Ewald
- Institut Paoli-Calmettes, Marseille, France
| | - O Turini
- Institut Paoli-Calmettes, Marseille, France
| | - A Thobie
- Hospital University Centre of Caen Normandie, Caen, France
| | - B Menahem
- Hospital University Centre of Caen Normandie, Caen, France
| | - A Mulliri
- Hospital University Centre of Caen Normandie, Caen, France
| | - J Lubrano
- Hospital University Centre of Caen Normandie, Caen, France
| | - J Zemour
- Hospital University Centre of Saint-Pierre, Saint Pierre, Department of Réunion, France
| | - H Fagot
- Hospital University Centre of Saint-Pierre, Saint Pierre, Department of Réunion, France
| | - G Passot
- Hospital University Centre of Lyon Sud, Lyon, France
| | - E Gregoire
- La Timone Hospital, Hospital University Centre of Marseille, Marseille, France
| | - J Hardwigsen
- La Timone Hospital, Hospital University Centre of Marseille, Marseille, France
| | - Y-P le Treut
- La Timone Hospital, Hospital University Centre of Marseille, Marseille, France
| | - D Patrice
- Louis Pasteur Hospital, Colmar, France
| |
Collapse
|
9
|
Diéras V, Han HS, Robson ME, Palácová M, Marcom PK, Jager A, Bondarenko I, Citrin D, Campone M, Telli ML, Domchek SM, Friedlander M, Kaufman B, Ratajczak C, Coates A, Bonnet P, Qin Q, Qian J, Giranda VL, Shepherd SP, Puhalla S, Isakoff SJ. Abstract P4-22-02: Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-22-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: V is a potent, poly(ADP-ribose) polymerase (PARP) inhibitor that obstructs DNA damage repair. BRCA1/2 tumors are defective in homologous recombination, which leads to more error-prone mechanisms of DNA repair and increased sensitivity to PARP inhibition. V enhances the antitumor activity of alkylating agents such as TMZ in preclinical models. In addition, V+TMZ showed promising activity in a single-arm phase 2 study in pts with BRCA1/2 mutations. This phase 2 trial (NCT01506609) investigated the efficacy and tolerability of V+TMZ (or V+C/P) compared to Plc+C/P in pts with locally recurrent or metastatic breast cancer harboring a BRCA1 or BRCA2 mutation. Results from the primary analysis for the V+TMZ arm vs Plc+C/P are presented, and the V+C/P vs Plc+C/P results will be presented separately.
Methods: Male and female pts aged ≥18 years with histologically confirmed locally recurrent or metastatic breast cancer were randomized 1:1:1 to: 1) V 40 mg BID D1–7 + TMZ 150–200 mg/m2 QD D1–5, 28-D cycle; 2) V 120 mg BID D1–7 + C AUC 6, D3 and P 175 mg/m2, D3, 21-D cycle; 3) placebo BID D1–7 + C/P. Key eligibility criteria included known deleterious BRCA1/2 mutation, ≤2 prior chemotherapies for metastatic disease, no prior platinum agent, and no CNS metastases. Randomization was stratified by hormone receptor status, prior cytotoxic therapy (yes vs no), and ECOG PS (0–1 vs 2). The primary endpoint was progression-free survival (PFS) per RECIST 1.1 by independent review. Overall survival (OS), objective response rate (ORR), and safety/tolerability were also evaluated.
Results: A total of 290 pts (284 BRCA+ per central lab) were randomized (V+TMZ, n=94 [91 BRCA+]). Baseline demographics and disease characteristics were comparable among treatment arms; 41.3% of pts had triple-negative breast cancer (TNBC) and 31.7% had received >2 prior regimens. Median study drug exposure was 6 cycles for the V+TMZ arm and 10 cycles for the Plc+C/P arm. Median PFS, median OS (interim), and ORR for V+TMZ were inferior to Plc+C/P (PFS 7.4 vs 12.3 mo, OS 19.1 vs 25.0 mo, and ORR 28.6% vs 61.3%). In pts with TNBC, median PFS was 5.5 (3.1–8.5) mo; 8.4 (6.8–10.6) mo for pts with non-TNBC. Treatment-emergent adverse events (AEs) of interest occurring differentially with V+TMZ are shown in Table 1. Grade ≥3 AEs in ≥30% of pts in the V+TMZ arm were thrombocytopenia (48%) and neutropenia (37%).
Conclusions: V+TMZ provided durable responses, with less neutropenia, alopecia, and neuropathy than Plc+C/P; however, PFS, OS, and ORR were inferior in the TMZ arm compared to C/P.
Table 1Treatment-Emergent AEs, n (%)V+TMZ, n=93Plc+C/P, n=96Neutropenia46 (50)71 (74)Alopecia10 (11)55 (57)Peripheral neuropathy11 (12)56 (58)Thrombocytopenia73 (79)67 (70)Nausea70 (75)56 (58)
Citation Format: Diéras V, Han HS, Robson ME, Palácová M, Marcom PK, Jager A, Bondarenko I, Citrin D, Campone M, Telli ML, Domchek SM, Friedlander M, Kaufman B, Ratajczak C, Coates A, Bonnet P, Qin Q, Qian J, Giranda VL, Shepherd SP, Puhalla S, Isakoff SJ. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-22-02.
Collapse
Affiliation(s)
- V Diéras
- Institut Curie, Paris, France; Moffitt Cancer Center, Tampa, FL; Memorial Sloan Kettering Cancer Center, New York, NY; Masarykův Onkologický ústav, Brno, Czech Republic; Duke University, Durham, NC; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Dnepropetrovsk City Hospital, Dnepropetrovsk, Ukraine; Midwestern Regional Medical Center, Zion, IL; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Stanford University School of Medicine, Stanford, CA; University of Pennsylvania, Philadelphia, PA; Prince of Wales Hospital, Sydney, NSW, Australia; Sheba Medical Center, Tel Hashomer, Israel; AbbVie, Inc, Chicago, IL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Massachusetts General Hospital, Boston, MA
| | - HS Han
- Institut Curie, Paris, France; Moffitt Cancer Center, Tampa, FL; Memorial Sloan Kettering Cancer Center, New York, NY; Masarykův Onkologický ústav, Brno, Czech Republic; Duke University, Durham, NC; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Dnepropetrovsk City Hospital, Dnepropetrovsk, Ukraine; Midwestern Regional Medical Center, Zion, IL; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Stanford University School of Medicine, Stanford, CA; University of Pennsylvania, Philadelphia, PA; Prince of Wales Hospital, Sydney, NSW, Australia; Sheba Medical Center, Tel Hashomer, Israel; AbbVie, Inc, Chicago, IL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Massachusetts General Hospital, Boston, MA
| | - ME Robson
- Institut Curie, Paris, France; Moffitt Cancer Center, Tampa, FL; Memorial Sloan Kettering Cancer Center, New York, NY; Masarykův Onkologický ústav, Brno, Czech Republic; Duke University, Durham, NC; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Dnepropetrovsk City Hospital, Dnepropetrovsk, Ukraine; Midwestern Regional Medical Center, Zion, IL; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Stanford University School of Medicine, Stanford, CA; University of Pennsylvania, Philadelphia, PA; Prince of Wales Hospital, Sydney, NSW, Australia; Sheba Medical Center, Tel Hashomer, Israel; AbbVie, Inc, Chicago, IL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Massachusetts General Hospital, Boston, MA
| | - M Palácová
- Institut Curie, Paris, France; Moffitt Cancer Center, Tampa, FL; Memorial Sloan Kettering Cancer Center, New York, NY; Masarykův Onkologický ústav, Brno, Czech Republic; Duke University, Durham, NC; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Dnepropetrovsk City Hospital, Dnepropetrovsk, Ukraine; Midwestern Regional Medical Center, Zion, IL; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Stanford University School of Medicine, Stanford, CA; University of Pennsylvania, Philadelphia, PA; Prince of Wales Hospital, Sydney, NSW, Australia; Sheba Medical Center, Tel Hashomer, Israel; AbbVie, Inc, Chicago, IL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Massachusetts General Hospital, Boston, MA
| | - PK Marcom
- Institut Curie, Paris, France; Moffitt Cancer Center, Tampa, FL; Memorial Sloan Kettering Cancer Center, New York, NY; Masarykův Onkologický ústav, Brno, Czech Republic; Duke University, Durham, NC; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Dnepropetrovsk City Hospital, Dnepropetrovsk, Ukraine; Midwestern Regional Medical Center, Zion, IL; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Stanford University School of Medicine, Stanford, CA; University of Pennsylvania, Philadelphia, PA; Prince of Wales Hospital, Sydney, NSW, Australia; Sheba Medical Center, Tel Hashomer, Israel; AbbVie, Inc, Chicago, IL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Massachusetts General Hospital, Boston, MA
| | - A Jager
- Institut Curie, Paris, France; Moffitt Cancer Center, Tampa, FL; Memorial Sloan Kettering Cancer Center, New York, NY; Masarykův Onkologický ústav, Brno, Czech Republic; Duke University, Durham, NC; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Dnepropetrovsk City Hospital, Dnepropetrovsk, Ukraine; Midwestern Regional Medical Center, Zion, IL; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Stanford University School of Medicine, Stanford, CA; University of Pennsylvania, Philadelphia, PA; Prince of Wales Hospital, Sydney, NSW, Australia; Sheba Medical Center, Tel Hashomer, Israel; AbbVie, Inc, Chicago, IL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Massachusetts General Hospital, Boston, MA
| | - I Bondarenko
- Institut Curie, Paris, France; Moffitt Cancer Center, Tampa, FL; Memorial Sloan Kettering Cancer Center, New York, NY; Masarykův Onkologický ústav, Brno, Czech Republic; Duke University, Durham, NC; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Dnepropetrovsk City Hospital, Dnepropetrovsk, Ukraine; Midwestern Regional Medical Center, Zion, IL; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Stanford University School of Medicine, Stanford, CA; University of Pennsylvania, Philadelphia, PA; Prince of Wales Hospital, Sydney, NSW, Australia; Sheba Medical Center, Tel Hashomer, Israel; AbbVie, Inc, Chicago, IL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Massachusetts General Hospital, Boston, MA
| | - D Citrin
- Institut Curie, Paris, France; Moffitt Cancer Center, Tampa, FL; Memorial Sloan Kettering Cancer Center, New York, NY; Masarykův Onkologický ústav, Brno, Czech Republic; Duke University, Durham, NC; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Dnepropetrovsk City Hospital, Dnepropetrovsk, Ukraine; Midwestern Regional Medical Center, Zion, IL; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Stanford University School of Medicine, Stanford, CA; University of Pennsylvania, Philadelphia, PA; Prince of Wales Hospital, Sydney, NSW, Australia; Sheba Medical Center, Tel Hashomer, Israel; AbbVie, Inc, Chicago, IL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Massachusetts General Hospital, Boston, MA
| | - M Campone
- Institut Curie, Paris, France; Moffitt Cancer Center, Tampa, FL; Memorial Sloan Kettering Cancer Center, New York, NY; Masarykův Onkologický ústav, Brno, Czech Republic; Duke University, Durham, NC; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Dnepropetrovsk City Hospital, Dnepropetrovsk, Ukraine; Midwestern Regional Medical Center, Zion, IL; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Stanford University School of Medicine, Stanford, CA; University of Pennsylvania, Philadelphia, PA; Prince of Wales Hospital, Sydney, NSW, Australia; Sheba Medical Center, Tel Hashomer, Israel; AbbVie, Inc, Chicago, IL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Massachusetts General Hospital, Boston, MA
| | - ML Telli
- Institut Curie, Paris, France; Moffitt Cancer Center, Tampa, FL; Memorial Sloan Kettering Cancer Center, New York, NY; Masarykův Onkologický ústav, Brno, Czech Republic; Duke University, Durham, NC; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Dnepropetrovsk City Hospital, Dnepropetrovsk, Ukraine; Midwestern Regional Medical Center, Zion, IL; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Stanford University School of Medicine, Stanford, CA; University of Pennsylvania, Philadelphia, PA; Prince of Wales Hospital, Sydney, NSW, Australia; Sheba Medical Center, Tel Hashomer, Israel; AbbVie, Inc, Chicago, IL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Massachusetts General Hospital, Boston, MA
| | - SM Domchek
- Institut Curie, Paris, France; Moffitt Cancer Center, Tampa, FL; Memorial Sloan Kettering Cancer Center, New York, NY; Masarykův Onkologický ústav, Brno, Czech Republic; Duke University, Durham, NC; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Dnepropetrovsk City Hospital, Dnepropetrovsk, Ukraine; Midwestern Regional Medical Center, Zion, IL; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Stanford University School of Medicine, Stanford, CA; University of Pennsylvania, Philadelphia, PA; Prince of Wales Hospital, Sydney, NSW, Australia; Sheba Medical Center, Tel Hashomer, Israel; AbbVie, Inc, Chicago, IL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Massachusetts General Hospital, Boston, MA
| | - M Friedlander
- Institut Curie, Paris, France; Moffitt Cancer Center, Tampa, FL; Memorial Sloan Kettering Cancer Center, New York, NY; Masarykův Onkologický ústav, Brno, Czech Republic; Duke University, Durham, NC; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Dnepropetrovsk City Hospital, Dnepropetrovsk, Ukraine; Midwestern Regional Medical Center, Zion, IL; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Stanford University School of Medicine, Stanford, CA; University of Pennsylvania, Philadelphia, PA; Prince of Wales Hospital, Sydney, NSW, Australia; Sheba Medical Center, Tel Hashomer, Israel; AbbVie, Inc, Chicago, IL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Massachusetts General Hospital, Boston, MA
| | - B Kaufman
- Institut Curie, Paris, France; Moffitt Cancer Center, Tampa, FL; Memorial Sloan Kettering Cancer Center, New York, NY; Masarykův Onkologický ústav, Brno, Czech Republic; Duke University, Durham, NC; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Dnepropetrovsk City Hospital, Dnepropetrovsk, Ukraine; Midwestern Regional Medical Center, Zion, IL; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Stanford University School of Medicine, Stanford, CA; University of Pennsylvania, Philadelphia, PA; Prince of Wales Hospital, Sydney, NSW, Australia; Sheba Medical Center, Tel Hashomer, Israel; AbbVie, Inc, Chicago, IL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Massachusetts General Hospital, Boston, MA
| | - C Ratajczak
- Institut Curie, Paris, France; Moffitt Cancer Center, Tampa, FL; Memorial Sloan Kettering Cancer Center, New York, NY; Masarykův Onkologický ústav, Brno, Czech Republic; Duke University, Durham, NC; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Dnepropetrovsk City Hospital, Dnepropetrovsk, Ukraine; Midwestern Regional Medical Center, Zion, IL; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Stanford University School of Medicine, Stanford, CA; University of Pennsylvania, Philadelphia, PA; Prince of Wales Hospital, Sydney, NSW, Australia; Sheba Medical Center, Tel Hashomer, Israel; AbbVie, Inc, Chicago, IL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Massachusetts General Hospital, Boston, MA
| | - A Coates
- Institut Curie, Paris, France; Moffitt Cancer Center, Tampa, FL; Memorial Sloan Kettering Cancer Center, New York, NY; Masarykův Onkologický ústav, Brno, Czech Republic; Duke University, Durham, NC; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Dnepropetrovsk City Hospital, Dnepropetrovsk, Ukraine; Midwestern Regional Medical Center, Zion, IL; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Stanford University School of Medicine, Stanford, CA; University of Pennsylvania, Philadelphia, PA; Prince of Wales Hospital, Sydney, NSW, Australia; Sheba Medical Center, Tel Hashomer, Israel; AbbVie, Inc, Chicago, IL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Massachusetts General Hospital, Boston, MA
| | - P Bonnet
- Institut Curie, Paris, France; Moffitt Cancer Center, Tampa, FL; Memorial Sloan Kettering Cancer Center, New York, NY; Masarykův Onkologický ústav, Brno, Czech Republic; Duke University, Durham, NC; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Dnepropetrovsk City Hospital, Dnepropetrovsk, Ukraine; Midwestern Regional Medical Center, Zion, IL; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Stanford University School of Medicine, Stanford, CA; University of Pennsylvania, Philadelphia, PA; Prince of Wales Hospital, Sydney, NSW, Australia; Sheba Medical Center, Tel Hashomer, Israel; AbbVie, Inc, Chicago, IL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Massachusetts General Hospital, Boston, MA
| | - Q Qin
- Institut Curie, Paris, France; Moffitt Cancer Center, Tampa, FL; Memorial Sloan Kettering Cancer Center, New York, NY; Masarykův Onkologický ústav, Brno, Czech Republic; Duke University, Durham, NC; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Dnepropetrovsk City Hospital, Dnepropetrovsk, Ukraine; Midwestern Regional Medical Center, Zion, IL; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Stanford University School of Medicine, Stanford, CA; University of Pennsylvania, Philadelphia, PA; Prince of Wales Hospital, Sydney, NSW, Australia; Sheba Medical Center, Tel Hashomer, Israel; AbbVie, Inc, Chicago, IL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Massachusetts General Hospital, Boston, MA
| | - J Qian
- Institut Curie, Paris, France; Moffitt Cancer Center, Tampa, FL; Memorial Sloan Kettering Cancer Center, New York, NY; Masarykův Onkologický ústav, Brno, Czech Republic; Duke University, Durham, NC; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Dnepropetrovsk City Hospital, Dnepropetrovsk, Ukraine; Midwestern Regional Medical Center, Zion, IL; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Stanford University School of Medicine, Stanford, CA; University of Pennsylvania, Philadelphia, PA; Prince of Wales Hospital, Sydney, NSW, Australia; Sheba Medical Center, Tel Hashomer, Israel; AbbVie, Inc, Chicago, IL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Massachusetts General Hospital, Boston, MA
| | - VL Giranda
- Institut Curie, Paris, France; Moffitt Cancer Center, Tampa, FL; Memorial Sloan Kettering Cancer Center, New York, NY; Masarykův Onkologický ústav, Brno, Czech Republic; Duke University, Durham, NC; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Dnepropetrovsk City Hospital, Dnepropetrovsk, Ukraine; Midwestern Regional Medical Center, Zion, IL; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Stanford University School of Medicine, Stanford, CA; University of Pennsylvania, Philadelphia, PA; Prince of Wales Hospital, Sydney, NSW, Australia; Sheba Medical Center, Tel Hashomer, Israel; AbbVie, Inc, Chicago, IL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Massachusetts General Hospital, Boston, MA
| | - SP Shepherd
- Institut Curie, Paris, France; Moffitt Cancer Center, Tampa, FL; Memorial Sloan Kettering Cancer Center, New York, NY; Masarykův Onkologický ústav, Brno, Czech Republic; Duke University, Durham, NC; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Dnepropetrovsk City Hospital, Dnepropetrovsk, Ukraine; Midwestern Regional Medical Center, Zion, IL; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Stanford University School of Medicine, Stanford, CA; University of Pennsylvania, Philadelphia, PA; Prince of Wales Hospital, Sydney, NSW, Australia; Sheba Medical Center, Tel Hashomer, Israel; AbbVie, Inc, Chicago, IL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Massachusetts General Hospital, Boston, MA
| | - S Puhalla
- Institut Curie, Paris, France; Moffitt Cancer Center, Tampa, FL; Memorial Sloan Kettering Cancer Center, New York, NY; Masarykův Onkologický ústav, Brno, Czech Republic; Duke University, Durham, NC; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Dnepropetrovsk City Hospital, Dnepropetrovsk, Ukraine; Midwestern Regional Medical Center, Zion, IL; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Stanford University School of Medicine, Stanford, CA; University of Pennsylvania, Philadelphia, PA; Prince of Wales Hospital, Sydney, NSW, Australia; Sheba Medical Center, Tel Hashomer, Israel; AbbVie, Inc, Chicago, IL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Massachusetts General Hospital, Boston, MA
| | - SJ Isakoff
- Institut Curie, Paris, France; Moffitt Cancer Center, Tampa, FL; Memorial Sloan Kettering Cancer Center, New York, NY; Masarykův Onkologický ústav, Brno, Czech Republic; Duke University, Durham, NC; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Dnepropetrovsk City Hospital, Dnepropetrovsk, Ukraine; Midwestern Regional Medical Center, Zion, IL; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Stanford University School of Medicine, Stanford, CA; University of Pennsylvania, Philadelphia, PA; Prince of Wales Hospital, Sydney, NSW, Australia; Sheba Medical Center, Tel Hashomer, Israel; AbbVie, Inc, Chicago, IL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Massachusetts General Hospital, Boston, MA
| |
Collapse
|